These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 12684393)

  • 1. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCOR1 mRNA is an independent prognostic factor for breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H
    Cancer Lett; 2006 Jun; 237(1):123-9. PubMed ID: 16019133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
    Ariazi EA; Clark GM; Mertz JE
    Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
    Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
    Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
    Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
    Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
    Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.
    Bièche I; Parfait B; Noguès C; Andrieu C; Vidaud D; Spyratos F; Lidereau R; Vidaud M
    Oncogene; 2001 Oct; 20(47):6955-9. PubMed ID: 11687975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
    Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.